Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 505,289 shares of the biotechnology company’s stock after buying an additional 22,225 shares during the period. Robeco Institutional Asset Management B.V. owned 0.18% of Exelixis worth $16,826,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in EXEL. Los Angeles Capital Management LLC increased its position in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Exelixis in the third quarter valued at approximately $14,979,000. Burney Co. acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $12,267,000. Retirement Systems of Alabama increased its holdings in shares of Exelixis by 24.6% in the third quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock valued at $23,653,000 after purchasing an additional 180,021 shares during the period. Finally, Tri Ri Asset Management Corp acquired a new position in shares of Exelixis in the third quarter valued at approximately $4,396,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on EXEL shares. Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $30.00 to $40.00 in a report on Monday, January 27th. Piper Sandler boosted their target price on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, January 13th. Truist Financial boosted their target price on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Stephens reissued an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a report on Monday, January 27th. Finally, Bank of America lowered Exelixis from a “buy” rating to a “neutral” rating and boosted their target price for the company from $35.00 to $39.00 in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and a consensus price target of $36.06.

Insider Transactions at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. This trade represents a 16.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 208,574 shares of company stock valued at $7,376,374 over the last three months. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Performance

EXEL opened at $33.15 on Friday. The business’s fifty day moving average is $34.68 and its two-hundred day moving average is $30.08. The company has a market cap of $9.47 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a one year low of $20.01 and a one year high of $37.59.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the previous year, the firm posted $0.10 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts predict that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.